2310008M10Rik Inhibitors
Chemical inhibitors of 2310008M10Rik operate via different mechanisms to disrupt the functional activity of this protein. Wortmannin and LY294002 are both phosphoinositide 3-kinases (PI3K) inhibitors, which means they can impede the PI3K/AKT pathway, a critical signaling route that 2310008M10Rik may rely on for its activation or repression. By obstructing this pathway, these inhibitors directly impede the protein's ability to carry out its role within the cell. Similarly, U0126 and PD98059 are inhibitors that target MEK1/2, thereby preventing the activation of extracellular signal-regulated kinases (ERKs). ERKs are often implicated in a myriad of cellular processes, and their inhibition by U0126 and PD98059 can result in the suppression of 2310008M10Rik's function by disturbing the signaling cascades in which it may participate.
Furthermore, SB203580 and SP600125 target the p38 MAP kinase and JNK respectively, both of which are integral components of stress-activated kinase signaling pathways. These pathways can intersect or regulate the pathways of 2310008M10Rik, and the inhibition by these chemicals can lead to the suppression of the protein's activity. In addition, Dasatinib and Imatinib function by inhibiting Src family kinases, ABL kinases, and receptor tyrosine kinases, all of which are involved in signaling networks that may govern the activity of 2310008M10Rik. By blocking these kinases, Dasatinib and Imatinib can interrupt the regulatory mechanisms of the protein. Sorafenib and Sunitinib, as multi-targeted receptor tyrosine kinase inhibitors, also act to obstruct the kinases initiating the signaling cascades that involve 2310008M10Rik, leading to its functional inhibition. Lastly, Erlotinib and Rapamycin inhibit the epidermal growth factor receptor (EGFR) and the mTOR pathway respectively. The inhibition of these pathways by Erlotinib and Rapamycin can disrupt the downstream signaling that regulates 2310008M10Rik, thus curtailing the protein's activity within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinases (PI3K) inhibitor. Since PI3K can be involved in the activation of downstream signaling pathways that may regulate 2310008M10Rik, its inhibition by Wortmannin can lead to the functional inhibition of 2310008M10Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that can disrupt the PI3K/AKT pathway, which might be crucial for the function of 2310008M10Rik. The inhibition of PI3K/AKT pathway by LY294002 can therefore inhibit the function of 2310008M10Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of extracellular signal-regulated kinases (ERKs). ERKs may be part of the signaling cascade influencing 2310008M10Rik activity. Inhibition of MEK by PD98059 can thus inhibit the function of 2310008M10Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also an inhibitor of MEK1/2, preventing the activation of ERKs. Interrupting this pathway with U0126 can lead to the inhibition of 2310008M10Rik's function by halting the signaling processes it may be involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, SB203580 can disrupt the cellular processes that may be regulated by p38 MAPK, potentially leading to the functional inhibition of 2310008M10Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which, like p38, is involved in stress-activated kinase signaling pathways. These pathways may intersect with those involving 2310008M10Rik, and inhibition by SP600125 can lead to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib targets Src family kinases and ABL kinases, which are part of signaling networks that may interact with 2310008M10Rik. By inhibiting these kinases, Dasatinib can inhibit the pathways that regulate 2310008M10Rik's function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is an inhibitor of ABL kinase, and by inhibiting ABL, Imatinib can disrupt the signaling network that may include 2310008M10Rik. This can lead to the functional inhibition of 2310008M10Rik by interrupting its regulatory pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple receptor tyrosine kinases, which may initiate signaling cascades that involve 2310008M10Rik. The inhibition of these kinases by Sorafenib can therefore inhibit the function of 2310008M10Rik. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is another multi-targeted receptor tyrosine kinase inhibitor. By inhibiting these kinases, Sunitinib can block the signaling pathways that may be necessary for the function of 2310008M10Rik, leading to its inhibition. | ||||||